Current Clinical Trials

The Medical Research Center of Connecticut was founded by Gastroenterology Center of Connecticut physicians in 2000. Our mission is to provide high quality care to our patients offering the opportunity to participate in clinical trials involving established and promising new treatments for gastrointestinal and liver disease.

We are currently enrolling participants in the following studies:

Ulcerative Colitis
  • AbbVie Protocol M14-234

    A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
    More Information

  • AbbVie Protocol M14-033 (High Dose Induction)

    A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
    More Information

Crohn's
  • Protocol I6T-MC-AMAG  (SERENITY)

    A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects with Active Crohn’s Disease
    More Information

    Celgene Protocol GED-0301-CD-002

    A Phase 3, Randomized, Placebo-controlled, Double-blind, Multicenter, Induction Study to Investigate the Efficacy and Safety of GED-0301 For the Treatment of Subjects With Active Crohn's Disease
    More Information

  • Redhill Biopharma Protocol RHB-104 (Triple antibiotic MAP)

    A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease
    More Information

  • AbbVie Protocol M14-115 (Adalimumab high dose induction)

    A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Two Adalimumab Induction Regimens in Subjects With Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration
    More Information

  • Takeda (Vedolizumab) Protocol MLN 3031

    A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn’s Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
    More Information

IBS - Constipation
  • None at this time

IBS - Diarrhea
  • None at this time

Other Studies
  •  SeraTrials - Protocol 05035

    Prospective Collection of Samples for Research: Objective is to obtain blood and/or biological samples from donors who have or have been screened for a variety of identifying characteristics and associated illness, as well as normal controls

  • Eosinophilic Esophagitis (EoE)

    FLUTicasone in Eosinophilic esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects with Eosinophilic Esophagitis
    More Information

Registries
  • Legacy Registry P11-282

    A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA®(Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)

  • Entyvio PASS Registry

    Entyvio (vedolizumab) long-term safety study: An international observational prospective cohort study comparing vedolizumab to other biologic agents in patients with ulcerative colitis or Crohn’s Disease.
    More Information

C.Diff
  • Seres 012 - ECOSPOR III

    A Phase 3 Multicenter, RandomizeEd, Double-Blind, Placebo-COntrolled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults Who Have Received Antibacterial Drug Treatment for Recurrent CDI (RCDI).
    More Information

 

If you are interested in learning more about the Medical Research Center of Connecticut or the studies in which we participate, please contact Jennifer Nikolich, our Research Nurse Administrator, at (203) 281-5161.